melan-a analog peptide

Vaccineexperimental

Clinical trial activity

5 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started May 1, 1999 (NCT00112216)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • melan-a analog peptide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00559026Phase 1Sep 1, 2004ISTITUTO REGINA ELENA, Istituto Superiore di Sanità, University of Rome Tor Vergata
NCT00160992Phase 1Jul 1, 2004Barletta Foundation, Fond'action contre le cancer, National Center of Competence in Resaerch, Switzerland, University of Lausanne
NCT00112242Phase 1Feb 1, 2004Ludwig Institute for Cancer Research, University of Lausanne
NCT00112229Phase 1Apr 1, 2003Ludwig Institute for Cancer Research, University of Lausanne
NCT00112216Phase 1May 1, 1999Ludwig Institute for Cancer Research, University of Lausanne
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of LausanneAcademic/Hospital4411999
Ludwig Institute for Cancer ResearchAcademic/Hospital3011999
Barletta FoundationAcademic/Hospital1012004
Fond'action contre le cancerAcademic/Hospital1012004
ISTITUTO REGINA ELENAAcademic/Hospital1012004
Istituto Superiore di SanitàAcademic/Hospital1112004
National Center of Competence in Resaerch, SwitzerlandGovernment1012004
University of Rome Tor VergataAcademic/Hospital1012004
8 organizations
Page 1 / 1